The role of IKBKE signaling for the stiffness-induced phenotype was further tested using a pharmacological inhibitor of IKBKE [37], Amlexanox, a dual IKBKE/TBK1 inhibitor that is clinically used for the treatment of recurrent aphthous ulcers and asthma [38, 39]. This evidence concerns the gene TBK1 and asthma.